Future period of time, Huadong medicine revenue growth is still mainly from the medical business. While Huadong Pharmaceuticals has repeatedly emphasized the importance of its own innovative drug business, but from the company's actual operations, the medical business has instead become the company's biggest bright spot. In the new quarterly financial report of East China pharmaceuticals, the company's profits fell more than 30%, while the medical beauty business growth reached 63%, which acquired the British company, under the impact of the epidemic, still achieved more than 12% growth in performance, the performance is very bright. Some investors pointed out that the innovative drugs of East China's medicine is not very competitive, on the contrary, the medical beauty business unintentionally, becoming the company's biggest growth driver.
From public information can be seen, East China Pharmaceutical is from 2013, involved in the medical beauty market, at that time, East China Pharmaceutical just look at the rapid growth of the power of the medical beauty industry, so some acquisitions and business integration, and in a few years time, its hyaluronic acid brand into the domestic sales of the first product, which is also proof of its strong sales ability, is expected to the medical beauty business in the future. is expected to realize even greater growth.
In fact, East China Pharmaceutical in the field of medical aesthetic layout is very large, not only in the country has a large sales team, also has a number of R & D centers overseas, the entire industrial chain layout is complete, competitiveness before, in the future, the performance is expected to climb rapidly.
Reference:
Huadong Pharmaceuticals' product pipeline in the domestic market has also entered the harvest period. In April this year, the company's globally exclusive collagen stimulant long-lasting microspheres Ellans?YiYanShi was approved for listing by the NMPA, and will officially land in China in the second half of the year, which is expected to disrupt the traditional medical filler industry.
Huadong Medicine said, at present in the United States, the European Union and other mainstream markets or regions listed in the medical aesthetic products have a variety of non-invasive and minimally invasive products in line with the direction of the policy to encourage, but also in line with the policy to encourage the development of medical aesthetic products to register the work of the plan in Hainan, will be in accordance with the latest national policy to actively promote the landing work, with a view to the realization of the earliest possible in the Boao Lecheng Medical Tourism Zone in Hainan, the listing of the sale of the Advanced Zone.